Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension safety study of sacubitril/valsartan in Japanese pediatric heart failure patients
jRCT2041230115Completed
- Sponsor
- Novartis
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sacubitril + valsartan in heart failure (HF) and left ventricular systolic dysfunction (LVSD), sponsored by Novartis. Primary endpoint: Adverse Events. Started Dec 2023; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure (HF)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on jRCT2041230115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230115.